Author

H.C. Raatgeep

SERUM INFLAMMATORY PROTEIN PROFILING TO CORROBORATE SELECTION OF THERAPY NAÏVE MODERATE-TO-SEVERE PAEDIATRIC CROHN’S DISEASE PATIENTS ELIGIBLE FOR FIRST-LINE INFLIXIMAB
SERUM INFLAMMATORY PROTEIN PROFILING TO CORROBORATE SELECTION OF THERAPY NAÏVE MODERATE-TO-SEVERE PAEDIATRIC CROHN’S DISEASE PATIENTS ELIGIBLE FOR FIRST-LINE INFLIXIMAB

H.C. Raatgeep  et al.

Item 1 - 1 / 1
1